Public Release: 

Boston Children's Hospital study reveals first 6 months best for stimulating heart growth

Boston Children's Hospital

Boston, Mass (April 27, 2015) -- In a recent issue of Science Translational Medicine, Brian Polizzotti, PhD, Bernhard Kuhn, MD, Sangita Choudhury, PhD, and colleagues affiliated with the Boston Children's Hospital's Translational Research Center report that the optimal window of time to stimulate heart muscle cell regeneration (cardiomyocyte proliferation) in humans is the first six months of life.

"Our results suggest that early administration of neuregulin may provide a targeted and multipronged approach to prevent heart failure in infants with CHD. Beginning treatment as early as possible could save these hearts from long-term damage and symptoms of heart failure later in childhood," says Polizzotti.

The same group of Boston Children's Hospital researchers has proven that child hearts are more prone to cardiomyocyte proliferation than adult hearts are. They have also shown that the drug neruegulin stimulates cell cycling and improves overall heart function in adult mice with injured hearts. Neuregulin is currently under investigation as a drug treatment for heart failure in adults, but corresponding studies for pediatric applications had not been attempted before now. While heart attacks account for most instances of heart failure in adults, congenital heart disease (CHD) is the number one cause of heart failure in children. Based on their previous research, Polizzotti and Kuhn hypothesized that neuregulin would be just as effective against the unique forms of cardiac damage that cause heart failure in children.

Polizzotti and his team compared three groups of mice subject to the same kinds of cardiac damage present in many types of CHD (namely, increased scarring and a decreased ejection fraction, which is a measure of how much blood is pumped through the heart per contraction). One group of mice received their first neuregulin injections at birth, another received their first injections five days after birth, and a control group received daily injections of a neutral protein serum. The mice given neuregulin from birth were found to have a sustained increase in heart function, as observed by both echocardiogram and MRI.

The researchers also discovered that in the early administration group, stimulated proliferation of uninjured cardiomyocytes resulted in the formation of an additional 224,000 new heart cells. "We estimate that thirty-eight percent of the additional cardiomyocytes were present due to cardioprotection, while sixty-two percent were the result of regeneration," says Polizzotti.

After the mouse trial, Polizzotti and colleagues tested their hypothesis on human heart cells. They focused specifically on one type of heart disease, Tetrology of Fallot (TOF), which typically requires surgery soon after birth. Heart muscle cells were collected at the time of surgery and then cultured for three days with either neuregulin or a harmless serum. The results mirrored those from the mouse study: neuregulin stimulated cardiomyocytes to regenerate in the diseased heart muscle of infants less than 6 months old. Polizzotti plans to take this research farther by testing neuregulin in hearts with other types of CHD. "It will be interesting to see if the results from animal studies translate to live pediatric patients with diseased heart muscle," says Polizzotti.

###

About Boston Children's Hospital

Boston Children's Hospital is home to the world's largest research enterprise based at a pediatric medical center, where its discoveries have benefited both children and adults since1869. More than 1,100 scientists, including seven members of the National Academy of Sciences, 14 members of the Institute of Medicine and 14 members of the Howard Hughes Medical Institute comprise Boston Children's research community. Founded as a 20-bed hospital for children, Boston Children's today is a 395-bed comprehensive center for pediatric and adolescent health care. Boston Children's is also the primary pediatric teaching affiliate of Harvard Medical School.

For more information about research and clinical innovation at Boston Children's Hospital visit: http://vectorblog.org

To learn more about pediatric health visit our Thriving blog: http://childrenshospitalblog.org

Join the social discussion and tweet us @BostonChildrens
Follow Boston Children's Hospital on Facebook: http://on.bchil.org/1mJ9fxf
Follow Boston Children's Hospital on Youtube: http://on.bchil.org/1oJib5B

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.